| Home > Publications database > MHCquant2 refines immunopeptidomics tumor antigen discovery. |
| Journal Article | DKFZ-2025-01945 |
; ; ; ; ; ; ; ; ; ; ; ; ;
2025
BioMed Central
London
This record in other databases:

Please use a persistent id in citations: doi:10.1186/s13059-025-03763-8
Abstract: Confident identification of human leukocyte antigen (HLA)-presented peptides is crucial for advancing cancer immunotherapy. We present MHCquant2, a scalable and modular Nextflow pipeline integrated into nf-core as a reproducible, portable, and standardized workflow for immunopeptidomics. This integration allows a community-driven, robust solution for high-throughput analyses across operating systems and cloud infrastructures. MHCquant2 integrates open-source tools including OpenMS, DeepLC, and MS2PIP, improving peptide identifications by up to 27% across diverse MS platforms, particularly enriching low-abundant peptides. MHCquant2 demonstrates state-of-the-art performance on our novel benignMHCquant2 dataset (n = 92) and expands the benign human immunopeptidome by over 160,000 unique naturally presented HLA peptides.
Keyword(s): Humans (MeSH) ; Antigens, Neoplasm: immunology (MeSH) ; Peptides: immunology (MeSH) ; HLA Antigens: immunology (MeSH) ; Software (MeSH) ; Neoplasms: immunology (MeSH) ; Proteomics: methods (MeSH) ; HLA ; Immunopeptidomics ; Immunotherapy ; Mass spectrometry ; Nextflow ; Nf-core ; Open-source ; Pipeline ; Antigens, Neoplasm ; Peptides ; HLA Antigens
|
The record appears in these collections: |